NeoGe­nomics spends $125M to ex­pand ops; Cara hires Cel­gene ex­ec as CMO

→ Can­cer-fo­cused ge­net­ic test mak­er NeoGe­nomics $NEO said it would ac­quire to ac­quire Genop­tix, an on­col­o­gy lab­o­ra­to­ry that spe­cial­izes in hema­tol­ogy and sol­id tu­mor test­ing for $125 mil­lion in cash and 1 mil­lion shares of NeoGe­nomics com­mon stock. With the buy, NeoGe­nomics is set to ex­pand its cov­er­age of on­col­o­gy prac­tices and en­hance its cus­tomer reach.

→ Bio­phar­ma­ceu­ti­cal com­pa­ny Cara Ther­a­peu­tics $CARA, which is de­vel­op­ing treat­ments for itchy skin, has hired Joana Goncalves as chief med­ical of­fi­cer, to re­place Joseph Stauf­fer who is tran­si­tion­ing in­to a con­sult­ing role. Goncalves, who most re­cent­ly served as VP of med­ical af­fairs for der­ma­tol­ogy and neu­rol­o­gy at Cel­gene $CELG and worked on the biotech’s pso­ri­a­sis drug Ote­zla, is tasked with ex­e­cut­ing the late-stage de­vel­op­ment of Cara’s Ko­r­su­va, an ex­per­i­men­tal drug for chron­ic kid­ney dis­ease-as­so­ci­at­ed pru­ri­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER